The eye presents a challenge for drug delivery. Traditional drops and ointments have limitations in drug mobility to the back of the eye as well as patient compliance. Novel ophthalmic dosage forms including intracameral and intravitreal implants, drug-eluting punctal plugs, and suprachoroidal microparticles, are emerging to address these issues. Implants offer long-term drug delivery, reducing dosing frequency to increase medication effectiveness and patient comfort, improving eye care. Activities at ProMed run the gamut from initial feasibility projects to late stage clinical trial supply as we look to initiate our first commercial ophthalmic product manufacturing activities in 2026.
